1. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.
- Author
-
Skowron, KB, Skowron, KB, Pitroda, SP, Namm, JP, Balogun, O, Beckett, MA, Zenner, ML, Fayanju, O, Huang, X, Fernandez, C, Zheng, W, Qiao, G, Chin, R, Kron, SJ, Khodarev, NN, Posner, MC, Steinberg, GD, Weichselbaum, RR, Skowron, KB, Skowron, KB, Pitroda, SP, Namm, JP, Balogun, O, Beckett, MA, Zenner, ML, Fayanju, O, Huang, X, Fernandez, C, Zheng, W, Qiao, G, Chin, R, Kron, SJ, Khodarev, NN, Posner, MC, Steinberg, GD, and Weichselbaum, RR
- Abstract
Strategies to identify tumors at highest risk for treatment failure are currently under investigation for patients with bladder cancer. We demonstrate that flow cytometric detection of poorly differentiated basal tumor cells (BTCs), as defined by the co-expression of CD90, CD44 and CD49f, directly from patients with early stage tumors (T1-T2 and N0) and patient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor prognosis in patients with bladder cancer. Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique patterns of gene expression during bladder tumor cell differentiation. We found cell division cycle 25C (CDC25C) overexpression in poorly differentiated BTCs and determined that CDC25C expression predicts adverse survival independent of standard clinical and pathologic features in bladder cancer patients. Taken together, our findings support the utility of BTCs and bladder cancer PDX models in the discovery of novel molecular targets and predictive biomarkers for personalizing oncology care for patients.
- Published
- 2016